MX2015017950A - Metodos para el tratamiento de cancer de ovario. - Google Patents
Metodos para el tratamiento de cancer de ovario.Info
- Publication number
- MX2015017950A MX2015017950A MX2015017950A MX2015017950A MX2015017950A MX 2015017950 A MX2015017950 A MX 2015017950A MX 2015017950 A MX2015017950 A MX 2015017950A MX 2015017950 A MX2015017950 A MX 2015017950A MX 2015017950 A MX2015017950 A MX 2015017950A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- ovarian cancer
- fra
- subpopulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837543P | 2013-06-20 | 2013-06-20 | |
| PCT/US2014/043402 WO2014205342A2 (en) | 2013-06-20 | 2014-06-20 | Methods for treatment of ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017950A true MX2015017950A (es) | 2016-05-10 |
Family
ID=52105530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017950A MX2015017950A (es) | 2013-06-20 | 2014-06-20 | Metodos para el tratamiento de cancer de ovario. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20160311921A1 (https=) |
| EP (1) | EP3011013A4 (https=) |
| JP (1) | JP6383787B2 (https=) |
| AU (1) | AU2014284212B2 (https=) |
| BR (1) | BR112015031950A2 (https=) |
| CA (1) | CA2914237A1 (https=) |
| MX (1) | MX2015017950A (https=) |
| WO (1) | WO2014205342A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| AU2016323968B2 (en) * | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| WO2019099374A2 (en) * | 2017-11-14 | 2019-05-23 | University Of Virginia Patent Foundation | Compositions and methods for making and using bispecific antibodies |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| US20230074385A1 (en) * | 2019-12-23 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Method for producing eribulin-based antibody-drug conjugate |
| CN117741149A (zh) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | 一种用于卵巢癌细胞叶酸受体α的检测试剂盒及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| US6351666B1 (en) | 1998-02-27 | 2002-02-26 | Biofield Corp. | Method and apparatus for sensing and processing biopotentials |
| JP3952599B2 (ja) | 1998-07-16 | 2007-08-01 | 松下電器産業株式会社 | 映像表示装置および映像表示方法 |
| WO2000004711A1 (en) | 1998-07-16 | 2000-01-27 | Imageid Ltd. | Image identification and delivery system |
| US6694090B1 (en) | 1998-07-20 | 2004-02-17 | Thomson Licensing S.A. | Method and apparatus for dynamically overriding a ratings limit during playback of a digital program |
| DE69900584T3 (de) | 1998-07-21 | 2009-05-20 | Nxp B.V. | System zur übertragung von daten von einem datenträger nach einer station mittels eines oder zum mindest eines anderen hilfsträgersignals |
| IT1303624B1 (it) | 1998-07-22 | 2000-11-15 | Techint Spa | Dispositivo per elettrodeposizione a cella circonferenziale a flussidifferenziati. |
| DE19833226C1 (de) | 1998-07-23 | 2000-04-20 | Steuler Industriewerke Gmbh | Niederschlagsrohrbündel für Naßelektrofilter |
| DE19833340A1 (de) | 1998-07-24 | 2000-02-10 | Karlsruhe Forschzent | Wurmförmiger Arbeitsmechanismus |
| AU5311599A (en) | 1998-07-24 | 2000-02-14 | Ce Resources Pte Ltd | Array electrophoretic apparatus |
| CN1106227C (zh) | 1998-07-24 | 2003-04-23 | 宝洁公司 | 具有带有改进的汲取管的抽吸分取器的内置袋型包装物 |
| US6386399B1 (en) | 1998-07-24 | 2002-05-14 | Yoshino Kogyosho Co., Ltd. | Container with manual pump |
| IT1301872B1 (it) | 1998-07-24 | 2000-07-07 | Abb Adda S P A | Dispositivo di comando e controllo di interruttori di alta e mediatensione |
| WO2003094929A2 (en) * | 2002-05-06 | 2003-11-20 | University Of Utah Research Foundation | Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| WO2007002535A2 (en) * | 2005-06-24 | 2007-01-04 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer |
| US8986650B2 (en) * | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| AU2007335744A1 (en) * | 2006-12-20 | 2008-06-26 | Alberto A. Gabizon | Method for administration of pegylated liposomal doxorubicin |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| AU2011323124C1 (en) * | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| HUE049693T2 (hu) * | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására |
-
2014
- 2014-06-20 JP JP2016521841A patent/JP6383787B2/ja not_active Expired - Fee Related
- 2014-06-20 BR BR112015031950A patent/BR112015031950A2/pt not_active Application Discontinuation
- 2014-06-20 CA CA2914237A patent/CA2914237A1/en not_active Abandoned
- 2014-06-20 US US14/898,905 patent/US20160311921A1/en not_active Abandoned
- 2014-06-20 MX MX2015017950A patent/MX2015017950A/es unknown
- 2014-06-20 EP EP14813679.9A patent/EP3011013A4/en not_active Withdrawn
- 2014-06-20 WO PCT/US2014/043402 patent/WO2014205342A2/en not_active Ceased
- 2014-06-20 AU AU2014284212A patent/AU2014284212B2/en not_active Ceased
-
2019
- 2019-03-19 US US16/357,577 patent/US20190202930A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014205342A4 (en) | 2015-06-04 |
| WO2014205342A2 (en) | 2014-12-24 |
| EP3011013A4 (en) | 2017-03-15 |
| BR112015031950A2 (pt) | 2017-07-25 |
| EP3011013A2 (en) | 2016-04-27 |
| AU2014284212A1 (en) | 2015-12-17 |
| AU2014284212B2 (en) | 2019-09-12 |
| JP2016529484A (ja) | 2016-09-23 |
| CA2914237A1 (en) | 2014-12-24 |
| US20160311921A1 (en) | 2016-10-27 |
| WO2014205342A3 (en) | 2015-04-23 |
| US20190202930A1 (en) | 2019-07-04 |
| JP6383787B2 (ja) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
| CY1122642T1 (el) | Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου | |
| CY1122754T1 (el) | Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX346555B (es) | Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1). | |
| CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| MX2021002728A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| GEAP202114132A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
| MX2015017950A (es) | Metodos para el tratamiento de cancer de ovario. | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| WO2015011282A3 (en) | Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases | |
| MX2015005928A (es) | Metodos para tratar el cancer de ovario con antagonistas de dll4. | |
| TW201614237A (en) | Markers for identifying patients responsive to anti-PD-L1 antibody therapy | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |